Subscribe
360b-shutterstock-com-2-
360b / Shutterstock.com
6 August 2015Americas

European Commission approves Pfizer’s buyout of Hospira

The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.


Editor's picks

Bankruptcy judge approves $305m sale of genetics testing company
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

Editor's picks

Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025

More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

More features

Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations